A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia
NCT01212328 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1120
Last updated 2011-09-05
Summary
Background: Cardiovascular diseases (CVD) are currently the leading cause of death globally and Asian Indians will account for between 40-60% of the global CVD burden within the next 10-15 years. Risk factor control and preventive care are effective in reducing CVD events and mortality. The greatest gains in CVD prevention have been seen when early and target-driven interventions address multiple risk factors together. However, achieving control of even individual risk factors (blood glucose, blood pressure, or blood lipid targets) is poor, globally. Quality improvement schemes, like the proposed intervention, have shown promise in high-income countries, but are untested in South Asia; a region with a population at extraordinarily high CVD risk.
Objective: To test whether a clinic-based case management intervention (consisting of guidelines based treatment, care coordinator assistance and decision support software) to reduce cardiovascular disease (CVD) risk among Type 2 diabetes patients in South Asia, is more effective and sustainable compared to existing care.
Trial subjects and methods: The study will involve a total of 1120 patients attending 8 established out-patient clinics in South Asia (140 patients at each clinic). Patients enrolled in the trial will be randomly assigned to either the control (existing care) or the intervention group and will be followed up for an average of 30 months. The total trial duration is about 3.5 years, from mid-August 2010 to December 31, 2013.
Conditions
- Type 2 Diabetes Mellitus
- Hypertension
- Dyslipidaemia
Interventions
- OTHER
-
Care Coordinator + Decision Support Software
Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
- OTHER
-
Usual care
Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
United Health Group, USA
collaborator UNKNOWN -
All India Institute of Medical Sciences
collaborator OTHER -
Madras Diabetes Research Foundation, Chennai
collaborator UNKNOWN -
Aga Khan University
collaborator OTHER -
Public Health Foundation of India
lead OTHER
Principal Investigators
-
Dorairaj Prabhakaran, MD, DM, MSc. · Public Health Foundation of India
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 35 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-10-31
- Primary Completion
- 2013-12-31
- Completion
- 2014-06-30
Countries
- India
- Pakistan
Study Locations
More Related Trials
-
Effect of Integrated CKD Care Program in Early Diabetic Nephropathy in Primary Health Care Setting.
NCT02194790 ·Status: COMPLETED ·Phase: NA
-
Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT)
NCT02176278 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
NCT03118713 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)
NCT05004428 ·Status: COMPLETED
-
A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
NCT01572610 ·Status: TERMINATED ·Phase: PHASE2
-
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
NCT02251431 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine
NCT02011178 ·Status: WITHDRAWN ·Phase: NA
-
Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308
NCT03616392 ·Status: COMPLETED ·Phase: PHASE1
-
CANVAS - CANagliflozin cardioVascular Assessment Study
NCT01032629 ·Status: COMPLETED ·Phase: PHASE3
-
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
NCT03492580 ·Status: COMPLETED
-
Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients
NCT01382303 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients
NCT06326034 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients
NCT06365541 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.
NCT07288749 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)
NCT06128096 ·Status: RECRUITING
-
Incretin-based Drugs and the Risk of Heart Failure
NCT02456428 ·Status: COMPLETED
-
Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
NCT05033054 ·Status: COMPLETED
-
Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide
NCT02610088 ·Status: COMPLETED ·Phase: PHASE4
-
Dapagliflozin Effects on Epicardial Fat
NCT02235298 ·Status: COMPLETED ·Phase: PHASE4
-
Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure
NCT06140251 ·Status: RECRUITING
-
Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk
NCT01213212 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes Patients
NCT02208921 ·Status: COMPLETED
-
Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)
NCT01829256 ·Status: COMPLETED ·Phase: NA
-
Type 2 Diabetes With Antiplatelet Drugs
NCT05053828 ·Status: COMPLETED
-
Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment
NCT06547502 ·Status: COMPLETED ·Phase: PHASE1